This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 91/2/151    most recent 01.RES.0000028150.51130.36v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coussin, F. Articles by Nixon, G. F. Search for Related Content PubMed PubMed Citation Articles by Coussin, F. Articles by Nixon, G. F. Related Collections Calcium cycling/excitation-contraction coupling Cell signalling/signal transduction

(Circulation Research. 2002;91:151.)
© 2002 American Heart Association, Inc.

Cellular Biology

Comparison of Sphingosine 1-Phosphate–Induced Intracellular Signaling Pathways in Vascular Smooth Muscles

Differential Role in Vasoconstriction

Frederic Coussin, Roderick H. Scott, Alan Wise, Graeme F. Nixon

From the Department of Biomedical Sciences (F.C., R.H.S., G.F.N.), Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK; and 7TMR Systems Research Europe (A.W.), GlaxoSmithKline R&D, Stevenage, UK.

Correspondence to Graeme F. Nixon, Dept of Biomedical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK. E-mail g.f.nixon{at}abdn.ac.uk

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Sphingosine 1-phosphate (S1P), a lipid released from activated platelets, influences physiological processes in the cardiovascular system via activation of the endothelial differentiation gene (EDG/S1P) family of 7 transmembrane G protein–coupled receptors. In cultured vascular smooth muscle (VSM) cells, S1P signaling has been shown to stimulate proliferative responses; however, its role in vasoconstriction has not been examined. In the present study, the effects of S1P and EDG/S1P receptor expression were determined in rat VSM from cerebral artery and aorta. S1P induced constriction of cerebral artery, which was partly dependent on activation of p160^ROCK (Rho-kinase). S1P also induced activation of RhoA in cerebral artery with a similar time course to contraction. In aorta, S1P did not produce a constriction or RhoA activation. In VSM myocytes from cerebral arteries, stimulation with S1P gives rise to a global increase in [Ca²⁺]_i, initially generated via Ca²⁺ release from the sarcoplasmic reticulum by an inositol 1,4,5-trisphosphate–dependent pathway. In aorta VSM, a small increase in [Ca²⁺]_i was observed after stimulation at higher concentrations of S1P. S1P induced activation of p42/p44^mapk in aorta and cerebral artery VSM. Subtype-specific S1P receptor antibodies revealed that the expression of S1P₃/EDG-3 and S1P₂/EDG-5 receptors is 4-fold higher in cerebral artery compared with aorta. S1P₁/EDG-1 receptor expression was similar in both types of VSM. Therefore, the ability of S1P to act as a vasoactive mediator is dependent on the activation of associated signaling pathways and may vary in different VSM. This differential signaling may be related to the expression of S1P receptor subtypes.

Key Words: vascular smooth muscle • sphingosine 1-phosphate • cerebral artery • vasoconstriction

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Several studies have now shown that the bioactive sphingolipid, sphingosine 1-phosphate (S1P), is likely to play an important role in regulating cellular processes via activation of specific signal transduction pathways.^1–3 In the short-term, S1P-induced activation of several intracellular signaling pathways occurs, such as an increase in the intracellular calcium concentration ([Ca²⁺]_i),⁴ activation of the monomeric GTP-binding protein, p21^RhoA (RhoA),⁵ and activation of p42/p44 mitogen-activated protein kinase (p42/p44^mapk).^6,7 Through activation of these signaling pathways, S1P can induce longer term effects, such as proliferation, differentiation, and cell migration.¹

It is now clear that S1P-induced intracellular effects occur predominantly through activation of selective S1P receptors on the plasma membrane.² These receptors, belonging to the G protein–coupled receptor superfamily, originally known as EDG (endothelial differentiation gene) receptors.⁸ Several isoforms have now been cloned and S1P₁/EDG-1,⁵ S1P₂/EDG-5,⁹ S1P₃/EDG-3,¹⁰ S1P₄/EDG-6,¹¹ and S1P₅/EDG-8¹² have high affinities for S1P with EC₅₀s in the nmol/L range. Recent studies have investigated the delineation of activation for S1P-induced transduction pathways with specific S1P receptor subtypes.^13,14 In transfected cell lines, it has been demonstrated that increases in [Ca²⁺]_i are partly inhibited by pertussis toxin, suggesting involvement of G_i,¹³ although this effect can also occur via activation of G_q¹⁴ and production of inositol 1,4,5-trisphosphate (InsP₃). Cell lines overexpressing S1P₃ receptors, compared with S1P₁, have a more pronounced increase in [Ca²⁺]_i.^13,15 As with other receptors that couple to heterotrimeric G proteins, S1P receptors also activate the monomeric G protein, p21^RhoA (RhoA)⁵ possibly via G₁₂.¹⁶ A recent study with S1P₃ receptor knockout mice has demonstrated that, whereas S1P-induced InsP₃ production was significantly decreased in embryonic fibroblast cells, RhoA activation was unaffected.¹⁷ Through these in vitro studies, an understanding of selective S1P receptor signaling is emerging.

Recent studies have indicated the importance of S1P in the cardiovascular system, particularly its essential role in vascular development¹⁸ and potential role in cardiovascular diseases.^19,20 S1P is synthesized and stored by resting platelets and, after platelet activation, is released in high concentrations (nmol/L to µmol/L range).²¹ Both endothelial cells and VSM cells can be exposed to significant levels of S1P in vivo. In primary cultured VSM cells, S1P has a proliferative effect.^19,20 In addition to these mitogenic effects, release of S1P from activated platelets may also modulate more rapid events, such as vasoconstriction. Intravenous injections of S1P results in decreased blood flow²² and contraction in renal, mesenteric, and basilar arteries.^23,24 The expression of S1P receptors and the signal transduction pathways activated by S1P in freshly isolated blood vessels have not yet been determined.

In the present study, we have compared 2 different types of smooth muscle: rat cerebral artery and rat thoracic aorta. Freshly isolated rat cerebral arteries express S1P₁, S1P₂, and S1P₃ receptors. S1P induces a release of Ca²⁺ from intracellular stores and subsequent contraction. S1P can also activate RhoA in rat cerebral artery with a similar time course. In contrast, freshly isolated rat aorta expresses lower levels of S1P₂ and S1P₃ receptors compared with cerebral artery. In these cells, S1P at a physiological concentration range produces a negligible increase in [Ca²⁺]_i and does not activate RhoA. These results suggest an important role for S1P in regulating contractility of selective blood vessels after platelet activation. Evidence suggests that this select activation of signaling pathways may be partly dependent on the relative expression of specific S1P receptor subtypes.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Tissue Preparation and Tension Measurement
Sprague-Dawley rats (250 g; Harlan Olac, Oxford, UK) were maintained in accordance with Home Office (UK) regulations and were euthanized by inhalation of CO₂ followed by cervical dislocation. Thoracic aorta and cerebral arteries (middle and basilar) were placed into ice-cold HEPES-buffered Krebs solution. Arteries were cleaned of connective tissue, and the endothelium was removed by gentle rubbing of the lumen. Endothelium-denuded arterial rings were attached to a force transducer (AE801, SensoNor AS). After determining contractile responses to 143 mmol/L K⁺, rings were stimulated with either S1P or ET-1. In some experiments, the rings were incubated with 5 µmol/L S1P to obtain a stable plateau contraction before Y-27632 was applied.

Enzymatic Dissociation of VSM Myocytes
Smooth muscle cells from cerebral arteries and aorta were isolated by enzymatic dissociation. Briefly, tissues were transferred to a Ca²⁺-free Hanks solution consisting of (in mmol/L) 55 NaCl, 80 Na glutamate, 5.6 KCl, 2 MgCl₂, 10 glucose, and 10 HEPES (pH 7.4). Arteries were incubated for 20 minutes in solution containing 0.3 mg/mL papain (Sigma), 1 mg/mL dithioerythritol (Sigma), and 1 mg/mL BSA. Tissues were further incubated for 5 minutes in Hanks solution (37°C) supplemented with 1 mg/mL BSA, 0.8 mg/mL collagenase (Sigma), and 100 µmol/L CaCl₂. After several washes, tissues were triturated. Isolated smooth muscle cells were stored on glass-bottom dishes maintained at 4°C and used within 6 hours. Only cells that had an elongated morphology were used for imaging.

Imaging of [Ca²⁺]_i
Individual VSM myocytes were loaded with 2 µmol/L Fura-2 AM for 30 minutes in a solution containing (in mmol/L) 130 NaCl, 5.6 KCl, 1 MgCl2, 1.7 CaCl₂, 11 Glucose, and 10 HEPES (pH 7.4) followed by a 20 minute de-esterification period. A Zeiss Axiovert 200 inverted microscope, equipped with a cooled CCD camera (Photometrics) and a polychromatic illumination system (T.I.L.L. Photonics), was used to capture fluorescence images with excitations at 340 and 380 nm. The ratio of the fluorescence intensity between the pair of frames (FR340/380) was calculated after background subtraction. The MetaFluor 4.6 software (Universal Imaging Corporation) controlled the illuminator and camera, and performed image ratioing and analysis. Results are expressed as F340/380 ratio. Experiments were performed at room temperature (22 to 24°C).

Electrophysiological Measurements
The whole-cell mode of the patch clamp technique was used to record currents evoked by S1P in smooth muscle cells from cerebral arteries. Patch pipettes (resistances, 4 to 8 M) were filled with solution containing, in mmol/L (140 KCl, 0.1 CaCl₂, 2 MgCl_2, 10 HEPES, 1.1 EGTA, 2 ATP; pH 7.2). Whole-cell currents were measured with an Axoclamp 2A (Axon Instruments Inc) and recorded at a membrane potential of -30 mV. S1P was externally applied by low-pressure ejection about 50 to 100 µm away from the cell being recorded. Currents were captured and stored on digital audio tape using a digital tape recorder (DTR 1200, Biologic). Data were analyzed using a Tandon computer (Cambridge Electronic Design software, version 6.0).

Immunoblotting
Frozen tissue was added to lysis buffer and homogenized at 4°C in a Braun homogenizing vessel as previously described.²⁵ Protein was measured using a Lowry assay (Biorad) to ensure equal protein loading. In addition, samples were checked using Coomassie Blue–stained gels, and membranes were stained with Ponceau Red to confirm protein loading. Whole-cell homogenates were used for immunoblotting with G-specific antibodies (anti-G_q, anti-G₁₂, and anti-G₁₃, Santa Cruz Biotechnology) and anti-p42/p44^mapk antibodies (phospho- and pan-) (New England Biolabs). For S1P receptor immunoblots, homogenates were centrifuged at 100 000g for 1 hour and the supernatant discarded. Proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to a nitrocellulose membrane (Biorad) as previously described.²⁵ The membranes were immunoblotted with primary antibodies followed by detection with horseradish peroxidase–conjugated secondary antibodies. The immunoreactive bands were visualized using enhanced chemiluminescence and quantitated with an imaging densitometer (Biorad GS-690). Only blots that were entirely nonsaturated pixels (as determined using Multianalyst software, Biorad) were quantitated to ensure linearity of densitometric analysis.

Monoclonal anti-S1P₃/EDG-3 and anti-S1P₂/EDG-5 receptor antibodies were obtained commercially from Exalpha Biologicals and characterized previously. They do not cross-react with S1P₂/EDG-5 or S1P₃/EDG-3, respectively, or with LPA₁/EDG-2, LPA₂/EDG-4, or S1P₄/EDG-6. HEK cell overexpressing S1P₁/EDG-1 receptor also did not show any reactivity with the S1P₃/EDG-3 or S1P₂/EDG-5 receptor antibodies (see the online data supplement available at http://www.circresaha.org). In addition, S1P₃/EDG-3 receptor antibodies did not show any reactivity in HEK cells overexpressing S1P₁/EDG-1 or S1P₂/EDG-5. S1P₂/EDG-5 receptor antibodies also did not show any reactivity in HEK cells overexpressing S1P₁/EDG-1 or S1P₃/EDG-3 (see online data supplement). Purified polyclonal anti-S1P₁/EDG-1 receptor antiserum was raised in rabbit against the COOH-terminal (peptide sequence KDEGDNPETIMSSGNVNSSS) of the human S1P₁/EDG-1 receptor protein. This sequence is specific to the S1P₁/EDG-1 receptor. The S1P₁/EDG-1 antibody did not show any reactivity against HEK cells overexpressing S1P₃/EDG-3 or S1P₂/EDG-5 receptors.

Rho Activation Assay
The Sepharose-bound GST-Rhotekin-Rho Binding Domain (RBD) was used (Upstate Biotechnology). Tissues were dissected and denuded as described. In order to obtain sufficient tissue, the cerebral arteries from 5 rats were pooled for each sample. Three aortae were used per sample. Cerebral arteries and thoracic aorta were stimulated for 5 or 10 minutes with either S1P (10 µmol/L) or ET-1 (100 nmol/L) and quickly frozen in liquid nitrogen. Frozen tissues were homogenized in buffer containing 50 mmol/L Tris.HCl (pH 7.2), 1% Triton X-100, 0.5% deoxycholic acid, 0.1% SDS, 500 mmol/L NaCl, 10 mmol/L MgCl₂, 20 µg/mL each of leupeptin and aprotinin, and 1 mmol/L phenylmethylsulfonyl fluoride (PMSF). Homogenates were clarified by centrifugation and incubated with the Sepharose-bound GST-Rhotekin RBD for 45 minutes at 4°C. Beads were washed 3 times and GTP-RhoA bound to beads was eluted by boiling in Laemmli’s SDS buffer. Proteins from each extract were separated by SDS-PAGE and transferred to nitrocellulose membrane, followed by immunoblotting with a specific mouse monoclonal anti-RhoA antibody (Santa Cruz Biotechnology) and a horseradish peroxidase-conjugated secondary antibody. Densities of bands corresponding to precipitated RhoA (GTP-RhoA) and total RhoA were quantitated with an imaging densitometer (Biorad GS-690). The amount of GTP-RhoA was normalized for the total amount of RhoA present in each sample.

Analysis of Data
Data are expressed as mean±SEM. Significance was tested by means of Student’s t test. A value of P<0.05 was considered significant.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
S1P-Induced Intracellular Ca²⁺ Increase in VSM Myocytes From Cerebral Artery and Aorta
Transient intracellular Ca²⁺ increases were induced by extracellular application of S1P in myocytes from cerebral artery. Typically, the transients observed in single myocytes from cerebral artery exhibited a rapid increase in [Ca²⁺]_i followed by a slower decline (Figure 1A). The mean amplitude of the peak evoked by 1 µmol/L S1P was 0.45±0.01 ratio units (n=109). In contrast to cerebral artery, stimulation of aortic myocytes with S1P produced only a small Ca²⁺ increase (Figure 1A) at higher S1P concentrations (maximum 30 µmol/L 0.13±0.03 ratio units; n=32). In both VSM types, 100 nmol/L ET-1 evoked transient Ca²⁺ increases (Figure 1B). Amplitude of the ET-1 induced Ca²⁺ responses was similar in the two types of VSM (Figure 1C). Identical intracellular Ca²⁺ increases were induced in cerebral arteries and aorta after stimulation with 10 mmol/L caffeine (data not shown). S1P-induced increases in [Ca²⁺]_i with an EC₅₀ of 5 nmol/L (Figure 1D). The EC₅₀ for aorta was not calculated as it was in the nonphysiological range and a maximum could not be achieved.

View larger version (24K): [in this window] [in a new window]   Figure 1. S1P-induced increase in [Ca2+]i in VSM myocytes from rat cerebral artery but not from aortic VSM myocytes. Representative fluorescence ratio (FR340/380) traces of the effects of 1 µmol/L S1P (A) and 100 nmol/L ET-1 (B) on [Ca2+]i in fura 2–loaded freshly isolated myocytes from rat cerebral artery and aorta. Dots at the bottom of each trace represent time of addition of S1P. Compiled data showing the relative amplitude of peak increases in [Ca2+]i induced by S1P and ET-1 is shown in the bar graphs (C). Hatched bars represent cerebral artery; open bars, aorta. Data are mean±SEM with number of cells in parentheses. D, Relative increase in Ca2+ with increasing concentrations of S1P for cerebral artery (open circles) and aorta (filled circles). Results are mean±SEM derived from 20 to 40 cells for each S1P concentration.

As shown in Figure 2A, Ca²⁺ mobilization after stimulation with 1 µmol/L S1P propagates throughout the entire cerebral artery myocyte producing contraction. S1P produced Ca²⁺ oscillations in approximately 50% of the cerebral artery myocytes (not shown). The S1P-stimulated Ca²⁺ transient observed in cerebral arteries was concentration-dependent and saturable, indicative of a receptor-dependent response. The effects of thapsigargin in the generation of calcium responses to S1P were investigated. Such treatment almost completely abolished the Ca²⁺ increases evoked by 1 µmol/L S1P (Figure 2B). Removal of external Ca²⁺ (in the presence of 0.5 mmol/L EGTA) or application of 2 µmol/L nifedipine only slightly reduced the transient peak (Figure 2B). These results indicate that the peak increases in [Ca²⁺]_i evoked by S1P are due to calcium mobilization from intracellular stores. As S1P may stimulate the InsP₃ pathway, we used the phospholipase C (PLC) inhibitor U73122 and its inactive analogue U73343. Twenty minutes preincubation of cerebral artery myocytes with U73122 (1 µmol/L) greatly decreased the responsiveness to 1 µmol/L S1P, whereas the inactive analogue, U73343, had no effect on S1P-induced increases in [Ca²⁺]_i (Figure 2B). U73122 alone did not affect the resting Ca²⁺ level nor the caffeine-induced Ca²⁺ responses (data not shown), suggesting that it blocked the phosphatidylinositol-specific PLC without depleting the intracellular Ca²⁺ store. To further determine the Ca²⁺ signaling cascade evoked by S1P, we determined the effects of ryanodine, an inhibitor of the ryanodine receptor (RyR)/Ca²⁺-induced Ca²⁺-release (CICR). Perfusion with 10 µmol/L ryanodine for 30 minutes reduced approximately 60% the amplitude of S1P-induced Ca²⁺ release (Figure 2B).

View larger version (36K): [in this window] [in a new window]   Figure 2. Ca2+ responses evoked by S1P in fura 2–loaded freshly isolated cerebral artery VSM myocytes. A, Time-lapse pseudocolor images highlighting different phases of S1P-induced Ca2+ rise in cerebral artery myocytes. Images shown are nonsequential and time after 1 µmol/L S1P application is indicated on each panel. B, Bar graphs show peak increases in [Ca2+]i induced by 1 µmol/L S1P in control conditions and after the following treatments: incubation with 1 µmol/L thapsigargin (for 5 minutes); in Ca2+-free with 0.5 mmol/L EGTA containing solution for 30 seconds (a time sufficient to remove the voltage-dependent Ca2+ current); and in the presence of 2 µmol/L nifedipine. In a second set of experiments, the peak increases in [Ca2+]i induced by 1 µmol/L S1P were measured in control conditions and under the following conditions: extracellular application of 1 µmol/L U73122; extracellular application of 1 µmol/L U73343 (for 30 minutes) and 10 µmol/L ryanodine (for 30 minutes). Data are mean±SEM with number of cells in parentheses. *Values significantly different from control conditions; P<0.05. C, Current trace showing the outward current obtained in response to extracellular application of S1P.

S1P-Induced Ca²⁺-Activated Currents
In voltage-clamped cerebral artery myocytes (-30 mV), extracellular application of 1 µmol/L S1P activated outward currents (Figure 2C). These had a mean amplitude of 550±140 pA (n=8) with a reversal potential of -74 mV. In some cells (n=3), a fast transient inward current preceded the larger outward current and had a mean peak amplitude of -590±160 pA (not shown). These currents were inhibited by thapsigargin suggesting that S1P mobilizes Ca²⁺ from stores and subsequently activates Ca²⁺-dependent conductances.

S1P Induced Contraction of Cerebral Artery but not of Aorta
The effects of S1P on contraction were examined in denuded cerebral arteries and denuded aortic rings. Exposure of cerebral arteries to 5 µmol/L S1P produced a contractile response followed by prolonged plateau (Figure 3A). The S1P-evoked increase of tension developed slowly compared with KCl (143 mmol/L) or ET-1 (100 nmol/L)–induced contractions (data not shown) and corresponded to 35±5% (n=5) of the ET-1-induced contraction. In contrast, S1P did not change tension in aortic rings (Figure 3A). In cerebral artery myocytes, the time course of the S1P-induced rise in [Ca²⁺]_i was substantially quicker than the prolonged time course of contraction in cerebral artery rings (Figure 3B).

View larger version (29K): [in this window] [in a new window]   Figure 3. S1P-induced contraction and RhoA activation in rat cerebral arteries and aorta. A, Tension traces show the effects of 5 µmol/L S1P on thoracic aorta and middle cerebral artery. S1P evoked a rise in tension of cerebral artery followed by a sustained plateau. On washout, tension returned to baseline. No change in tension was observed after incubation of aorta with S1P. B, Time course and amplitude of the mean change in tension and mean Ca2+ increase after application of S1P. For tension data, n=6; for Ca2+ increase data, n=25. C, Cerebral artery with S1P (5 µmol/L). After maximum tension was reached, addition of the Rho-kinase inhibitor Y-27632 (10 µmol/L) reduced tension to baseline. D, Concentration-response curves showing inhibitory effect of Y-27632 on S1P (5 µmol/L)–induced tension in cerebral arteries (n=8). E, Increase in GTP-bound RhoA proportional to total RhoA after stimulation with either 10 µmol/L S1P or 100 nmol/L ET-1. CA indicates cerebral arteries; Ao, aorta. Panels show typical blots. Total-RhoA and GTP-RhoA are from the same samples. S1P increased the proportion of GTP-RhoA 4.2±0.6-fold (n=3) after 5 minutes of stimulation in cerebral arteries, compared with nontreated. S1P had a small effect on GTP-RhoA in aorta after 10 minutes of stimulation (1.5±0.1-fold increase, n=3). ET-1 increased the proportion of GTP-RhoA 5±1-fold in cerebral artery (n=3) and 5±0.4-fold in aorta (n=3).

Y-27632 (10 µmol/L) was used to assess the involvement of Rho-kinase in S1P-induced contraction of cerebral artery. Cerebral artery was stimulated with 5 µmol/L S1P and maximum tension achieved. After the addition of Y-27632, the tension decreased to baseline (Figures 3C and 3D).

Rho Activation
Stimulation with 10 µmol/L S1P increased the level of GTP-RhoA expressed as a proportion of total RhoA (Figure 3E). The association of the GST-Rhotekin RBD with GTP-RhoA is linearly proportional in smooth muscle homogenates as previously published.²⁶ The increase in GTP-RhoA was 4-fold after 5 minutes of stimulation with S1P. Stimulation with ET-1 in cerebral arteries also resulted in a 5-fold increase, compared with controls, in the proportion of GTP-bound RhoA to total RhoA. In aorta, a 10-minute incubation with S1P did not produce a significant increase in GTP-bound RhoA (1.5-fold). However, ET-1 (100 nmol/L) induced a 5-fold increase in GTP-bound RhoA.

Expression of S1P Receptor Subtypes, G_q and G_12/13, in Cerebral Arteries and Aorta VSM
The expression pattern of S1P receptors was examined using specific receptor subtype antibodies. All 3 subtypes examined were expressed in aorta and cerebral artery tissues (Figure 4). Densitometric measurements showed that the level of S1P₁ protein expression was similar in both tissues. However, the expression of both S1P₂ and S1P₃ receptors was increased 4-fold in the cerebral arteries compared with aorta (Figure 4). The relative expression of G_q, G₁₂, and G₁₃ was also assessed. G_q was slightly greater in cerebral arteries compared with aorta (1.4-fold; Figure 4). Expression of G₁₂ and G₁₃ was also slightly greater in cerebral artery compared with aorta (1.6-fold).

View larger version (36K): [in this window] [in a new window]   Figure 4. S1P receptor expression in membrane preparations from rat cerebral artery VSM and aorta VSM. A, Representative immunoblots stained with specific antibodies raised against S1P1, S1P2, and S1P3 receptors. A band at 45 kDa is visible in membrane preparations from aorta and cerebral artery (20 µg/lane), and from transfected HEK293 cells overexpressing human S1P1 receptor (10 µg/lane). Nontransfected HEK293 cells showed a faint band with anti-S1P1 receptor antibody after overexposure of blots. A single band of 48 to 51 kDa is identified on S1P2 and S1P3 receptor immunoblots in both VSM membrane preparations. Densitometric analysis showed similar levels of S1P1 protein expression in aorta compared with cerebral artery (n=4). S1P2 protein expression was greater in cerebral arteries compared with aorta (4.2±0.8-fold; n=4). Similarly, S1P3 protein expression was also 4.4±0.2-fold (n=4) greater in cerebral artery compared with aorta. Immunoblotting with anti-smooth muscle actin from the same samples demonstrate relative protein loading. B, Relative expression of Gq, G12, and G13 in cerebral artery compared with aorta. Levels of expression of Gq were slightly lower in aorta compared cerebral artery (1.4±0.3-fold in CA compared with Ao; n=3). Similarly expression of G12 and G13 were slightly lower in aorta compared with cerebral artery (G12 1.6±0.1-fold in CA compared with Ao; G13 1.4±0.2-fold in CA compared with Ao; n=3 for both).

p42/p44^mapk Activation
Cerebral artery and aorta were stimulated with 5 µmol/L S1P for 15 and 30 minutes and the activation of p42/p44^mapk was determined (Figure 5). p42/p44^mapk was stimulated 4-fold after 15 minutes and 5-fold after 30 minutes following incubation with S1P in aorta. In cerebral artery, p42/p44^mapk was increased 3-fold after 15 minutes and 4-fold after 30 minutes compared with the total p42/p44^mapk present.

View larger version (41K): [in this window] [in a new window]   Figure 5. Activation of p42/p44mapk by S1P in aorta and cerebral artery VSM. After 15 and 30 minutes incubation with 5 µmol/L S1P, cerebral artery (A) and aorta (B) revealed an increased activation of p42/p44mapk as measured by phospho-MAPK antibodies. These increases were 2.9±0.7-fold (15 minutes) and 4.2±0.9-fold (30 minutes) for cerebral artery; 3.9±0.7-fold (15 minutes) and 5.1±1.1-fold (30 minutes) for aorta; n=3 for all lanes.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
Recent studies suggest that S1P exerts diverse physiological actions by activating S1P receptors in cultured VSM cells.^18–20 However, the relative contribution of S1P in regulating vascular tone, and the intracellular mechanisms involved, has not yet been addressed. The aim of this study was to determine the effects of S1P on 2 types of freshly isolated vascular smooth muscle. The results of our studies demonstrate that S1P can act as a vasoactive substance in cerebral artery but not in aorta. S1P can produce a global increase of [Ca²⁺]_i by an InsP₃-mediated mechanism with a subsequent increase in tension in cerebral artery. S1P stimulation also resulted in an increase in GTP-bound RhoA, indicating RhoA activation, in a time course compatible with a role in cerebral artery vasoconstriction. Inhibition of the downstream effector of RhoA, Rho-kinase, results in a significant reversal in the tension produced by S1P. In aorta, similar concentrations of S1P do not appear to activate RhoA. The differential effects of S1P in different blood vessels may be due to alterations in upstream intracellular signaling proteins or membrane receptors. Although expression of G_12/13 and G_q were similar in the 2 types of VSM, the relative expression of S1P receptor subtypes was significantly different. Cerebral arteries expressed S1P₁, S1P₂, and S1P₃ receptor subtypes. Aorta also expressed these 3 subtypes; however, the expression of S1P₂ and S1P₃ was significantly lower compared with cerebral artery.

Although this study is the first to determine S1P receptor expression in fully differentiated VSM, the relative expression of the S1P receptor subtypes in cerebral artery smooth muscle compared with aorta smooth muscle suggest that different vascular beds may express varying levels of S1P receptor subtypes. As pharmacological tools are not yet available to dissect out roles for each subtype, a direct comparison of expression with function in isolated tissue, such as VSM, is difficult to address. In cell lines it has been established that experimental manipulation of the relative expression of S1P receptor isoforms, for example by overexpression, has functional consequences for specific S1P-induced intracellular effects.^5,13,15 This is also the case in cultured aortic VSM cells.²⁰ This study now suggests that in fully differentiated smooth muscle, a differential expression of S1P receptor subtypes may contribute to variations of the cellular responses to S1P in vivo. In rat aorta VSM, the lower relative expression (compared with cerebral artery) of S1P₂ and S1P₃ correlates with a lack of vasoconstriction and a greatly reduced S1P-induced global increase in [Ca²⁺]_i. Additionally, aorta VSM stimulated with S1P did not produce an activation of RhoA. (Because S1P₁, S1P₂, and S1P₃ receptors are present in aorta, some activation of RhoA may occur although the GST-rhotekin RBD "pulldown" assay utilized in this study would not detect such small increases). In cerebral artery, compared with aorta, the coupling of a greater S1P-induced increase in [Ca²⁺]_i and higher expression level (compared with aorta) of S1P₂ and S1P₃ agrees with several previous studies in various cell lines demonstrating a direct correlation of S1P₃ expression in particular and S1P-induced Ca²⁺ release.^13–15,17 In support of these functional data, S1P receptor subtypes, S1P₂ and S1P₃, can couple to G_q^13,15–17 linked to phospholipase C activation, whereas S1P₁ couples relatively selectively to G_i.^16,27 Results from our study would also suggest that RhoA activation occurs predominantly via S1P₂ and S1P₃ receptors. Both S1P₂ and S1P₃ (but not S1P₁) can couple to G₁₂,¹⁶ an upstream effector of RhoA activation.²⁸ In aorta, the expression of S1P receptors but the lack of S1P-induced vasoconstriction suggest that S1P may have other physiological effects in this VSM. S1P-induced stimulation of p42/p44^mapk was observed in aorta as well as in cerebral arteries. As activation of MAPK is associated with a proliferative response, S1P may be involved in the initiation of VSM proliferation as suggested in cultured aortic VSM cells,^19,20 possibly via S1P₁/G_i-coupled mechanism.²⁷

In cerebral VSM, S1P produced concentration-dependent increases in [Ca²⁺]_i with an EC₅₀ value similar to that of recombinant S1P receptors overexpressed in oocytes.¹⁴ The S1P-induced increase in [Ca²⁺]_i is probably the result of Ca²⁺ release from intracellular thapsigargin-sensitive stores because it fails to occur after inhibition of the sarcoplasmic reticulum Ca²⁺-ATPase. Moreover, removal of external Ca²⁺ or inhibition of voltage-gated Ca²⁺ channels had no significant effect on the S1P-induced Ca²⁺ response. U73122 completely abolished the [Ca²⁺]_i response to S1P, indicating S1P-induced Ca²⁺ transients were mediated by PLC activation and subsequent activation of InsP₃-gated Ca²⁺ release channels. Ryanodine decreased the S1P-induced increase in [Ca²⁺]_i, suggesting VSM cells use combined activation of InsP₃ receptors and of RyR/Ca²⁺-induced Ca²⁺ release channels to release and propagate global increases in intracellular Ca²⁺. The ability of InsP₃ pathway to recruit RyR to generate Ca²⁺ waves have been previously suggested in cerebral VSM.²⁹ The global increase in [Ca²⁺]_i is further shown by electrophysiological techniques. After S1P application, a global Ca²⁺ rise presumably activates a large Ca²⁺-sensitive K⁺ current,³⁰ promoting repolarization of the cell membrane. This would also negatively regulate contractility, ie, lead toward relaxation. However, in this case the predominating effect is maintained contractility, probably via activation of the RhoA pathway. For comparison, the effects of another vasoconstrictor, ET-1, on the [Ca²⁺]_i in isolated VSM myocytes from rat cerebral artery and aorta was determined. These were similar in both types of VSM. The characteristics of the increase in [Ca²⁺]_i in response to a maximal concentration of ET-1 in cerebral artery was similar to that observed for S1P.

Smooth muscle contractility is regulated by the Ca²⁺/calmodulin-dependent phosphorylation of the myosin regulatory light chains (MLCs). Increases in MLC phosphorylation can also occur at constant Ca²⁺ concentration through inhibition of the MLC phosphatase (ie, Ca²⁺ sensitization).³¹ It is now recognized that the p160 Rho-associated protein kinase (Rho-kinase), which is activated by RhoA, can phosphorylate the MLC phosphatase, inhibiting its activity.³² The ability of S1P to stimulate activation of RhoA in cerebral artery smooth muscle has important implications for its potential role as a vasoconstrictor. The prolonged contractile response obtained with S1P is not due to a sustained [Ca²⁺]_i and is likely due to RhoA activation. Rho-kinase inhibition reverses this prolonged contractile response³³ to S1P in agreement with a study in canine basilar arteries,²⁴ further demonstrating the involvement of the RhoA/Rho-kinase pathway in S1P-induced vasoconstriction. The ET-1–induced contraction in cerebral arteries was also decreased by Rho-kinase inhibition, as previously reported in other smooth muscles.³⁴ Despite similar Ca²⁺ release characteristics evoked by S1P and ET-1 in cerebral artery VSM, the contractile response of these vasoconstrictor agonists in whole arteries is different. The prolonged profile of the S1P-induced contraction is similar to that observed previously²⁴ and corresponds to its potential role in cerebral vasospasm, typified by a prolonged vasoconstriction. The ET-1–induced contraction is greater (60% to 70%) than the response to a maximal concentration of S1P. The reason for this difference is not yet clear but may be related to relative receptor efficacy.

In conclusion, this study has demonstrated that physiologically relevant concentrations of S1P can act as a vasoconstrictor in cerebral arteries, but not in aorta. Selectivity of this action may be the result of differential expression of S1P receptor isoforms, previously undetermined in native vascular smooth muscle. Therefore, in vivo, partial occlusion of the cerebral circulation by thrombus formation could result in the local release of S1P from platelets, producing a local vasoconstrictor response. This could further compromise cerebral blood flow and contribute to cerebral ischemia.

	Acknowledgments

 
This study was funded by The Wellcome Trust.

Received November 19, 2001; revision received June 20, 2002; accepted June 20, 2002.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 
1. Spiegel S, Milstien S. Functions of a new family of sphingosine-1-phosphate receptors. Biochim Biophys Acta. 2000; 1484: 107–116.[Medline] [Order article via Infotrieve]

2. Hla T. Sphingosine 1-phosphate receptors. Prostaglandins Other Lipid Mediat. 2001; 64: 135–142.[CrossRef][Medline] [Order article via Infotrieve]

3. Pyne S, Pyne N. Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors. Pharmacol Ther. 2000; 88: 115–131.[CrossRef][Medline] [Order article via Infotrieve]

4. Mattie M, Brooker G, Spiegel S. Sphingosine 1-phosphate, a putative second messenger, mobilizes calcium from internal stores via an inositol trisphosphate-independent pathway. J Biol Chem. 1994; 269: 3181–3188.[Abstract/Free Full Text]

5. Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, Spiegel S, Hla T. Sphingosine-1-phosphate as a ligand for the G protein–coupled receptor EDG-1. Science. 1998; 279: 1552–1555.[Abstract/Free Full Text]

6. Wu J, Spiegel S, Sturgill TW. Sphingosine 1-phosphate rapidly activates the mitogen-activated protein kinase pathway by a G protein–dependent mechanism. J Biol Chem. 1995; 270: 11484–11488.[Abstract/Free Full Text]

7. Rakhit S, Conway AM, Tate R, Bower T, Pyne NJ, Pyne S. Sphingosine 1-phosphate stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: role of endothelial differentiation gene 1, c-Src tyrosine kinase and phosphoinositide 3-kinase. Biochem J. 1999; 338: 643–649.[CrossRef][Medline] [Order article via Infotrieve]

8. Hla T, Maciag T. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein–coupled receptors. J Biol Chem. 1990; 265: 9308–9313.[Abstract/Free Full Text]

9. Okazaki H, Ishizaka N, Sakurai T, Kurokawa K, Goto K, Kumada M, Takuwa Y. Molecular-cloning of a novel putative G protein–coupled receptor expressed in the cardiovascular system. Biochem Biophys Res Commun. 1993; 190: 1104–1109.[CrossRef][Medline] [Order article via Infotrieve]

10. Yamaguchi F, Tokuda M, Hatase O, Brenner S. Molecular cloning of the novel human G protein–coupled receptor (GPCR) gene mapped on chromosome 9. Biochem Biophys Res Commun. 1996; 227: 608–614.[CrossRef][Medline] [Order article via Infotrieve]

11. Graler MH, Bernhardt G, Lipp M. EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. Genomics. 1998; 53: 164–169.[CrossRef][Medline] [Order article via Infotrieve]

12. Im DS, Heise CE, Ancellin N, O’Dowd BF, Shei GJ, Heavens RP, Rigby MR, Hla T, Mandala S, McAllister G, George SR, Lynch KR. Characterization of a novel sphingosine 1-phosphate receptor, EDG-8. J Biol Chem. 2000; 275: 14281–14286.[Abstract/Free Full Text]

13. An S, Bleu T, Zheng Y. Transduction of intracellular calcium signals through G protein-mediated activation of phospholipase C by recombinant sphingosine 1-phosphate receptors. Mol Pharmacol. 1999; 55: 787–794.[Abstract/Free Full Text]

14. Ancellin N, Hla T. Differential pharmacological properties and signal transduction of the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5. J Biol Chem. 1999; 274: 18997–19002.[Abstract/Free Full Text]

15. Sato K, Kon J, Tomura H, Osada M, Murata N, Kuwabara A, Watanabe T, Ohta H, Ui M, Okajima F. Activation of phospholipase C-Ca²⁺ system by sphingosine 1-phosphate in CHO cells transfected with Edg-3, a putative lipid receptor. FEBS Lett. 1999; 443: 25–30.[CrossRef][Medline] [Order article via Infotrieve]

16. Windh RT, Lee MJ, Hla T, An S, Barr AJ, Manning DR. Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G_i, G_q, and G₁₂ families of heterotrimeric G proteins. J Biol Chem. 1999; 274: 27351–27358.[Abstract/Free Full Text]

17. Ishii I, Friedman B, Ye X, Kawamura S, McGiffert C, Contos JJ, Kingsbury MA, Zhang G, Heller Brown J, Chun J. Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J Biol Chem. 2001; 276: 33697–33704.[Abstract/Free Full Text]

18. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S, Proia RL. Edg-1, the G protein–coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 2000; 106: 951–961.[Medline] [Order article via Infotrieve]

19. Tamama K, Kon J, Sato K, Tomura H, Kuwabara A, Kimura T, Kanda T, Ohta H, Ui M, Kobayashi I, Okajima F. Extracellular mechanism through the Edg family of receptors might be responsible for sphingosine-1-phosphate-induced regulation of DNA synthesis and migration of rat aortic smooth-muscle cells. Biochem J. 2001; 353: 139–146.[CrossRef][Medline] [Order article via Infotrieve]

20. Kluk MJ, Hla T. Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ Res. 2001; 89: 496–502.[Abstract/Free Full Text]

21. Yatomi Y, Ruan F, Hakomori S, Igarashi Y. Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets. Blood. 1995; 86: 193–202.[Abstract/Free Full Text]

22. Bischoff A, Czyborra P, Meyer Zu Heringdorf D, Jakobs KH, Michel MC. Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitive manner. Br J Pharmacol. 2000; 130: 1878–1883.[CrossRef][Medline] [Order article via Infotrieve]

23. Bischoff A, Czyborra P, Fetscher C, Meyer Zu Heringdorf D, Jakobs KH, Michel MC. Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. Br J Pharmacol. 2000; 130: 1871–1877.[CrossRef][Medline] [Order article via Infotrieve]

24. Tosaka M, Okajima F, Hashiba Y, Saito N, Nagano T, Watanabe T, Kimura T, Sasaki T. Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: Possible role in pathogenesis of cerebral vasospasm. Stroke. 2001; 32: 2913–2919.[Abstract/Free Full Text]

25. Tasker PN, Michelangeli F, Nixon GF. Expression and distribution of the type 1 and type 3 inositol 1,4,5-trisphosphate receptor in developing vascular smooth muscle. Circ Res. 1999; 84: 536–542.[Abstract/Free Full Text]

26. Sakurada S, Okamoto H, Takuwa N, Sugimoto N, Takuwa Y. Rho activation in excitatory agonist-stimulated vascular smooth muscle. Am J Physiol. 2001; 2001: 281:C571–C578.

27. Lee M-J, Evans M, Hla T. The inducible G protein–coupled receptor edg-1 signals via the G_i/mitogen-activated protein kinase pathway. J Biol Chem. 1996; 271: 11272–11279.[Abstract/Free Full Text]

28. Kozasa T, Jiang X, Hart MJ, Sternweis PM, Singer WD, Gilman AG, Bollag G, Sternweis PC. p115 RhoGEF, a GTPase activating protein for G₁₂ and G₁₃. Science. 1998; 280: 2109–2111.[Abstract/Free Full Text]

29. Jaggar JH, Nelson MT. Differential regulation of Ca²⁺ sparks and Ca²⁺ waves by UTP in rat cerebral artery smooth muscle cells. Am J Physiol. 2000; 279: C1528–C1539.

30. Brayden JE, Nelson MT. Regulation of arterial tone by activation of calcium-dependent potassium channels. Science. 1992; 256: 532–535.[Abstract/Free Full Text]

31. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol. 2000; 522: 177–185.[Abstract/Free Full Text]

32. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996; 273: 245–248.[Abstract]

33. Fu X, Gong MC, Jia T, Somlyo AV, Somlyo AP. The effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-, GTPS-, and phorbol ester-induced Ca²⁺-sensitization of smooth muscle. FEBS Lett. 1998; 440: 183–187.[CrossRef][Medline] [Order article via Infotrieve]

34. Yoshii A, Iizuka K, Dobashi K, Horie T, Harada T, Nakazawa T, Mori M. Relaxation of contracted rabbit tracheal and human bronchial smooth muscle by Y-27632 through inhibition of Ca²⁺ sensitization. Am J Respir Cell Mol Biol. 1999; 20: 1190–1200.[Abstract/Free Full Text]

This article has been cited by other articles:

				S.-K. Choi, D.-S. Ahn, and Y.-H. Lee Comparison of contractile mechanisms of sphingosylphosphorylcholine and sphingosine-1-phosphate in rabbit coronary artery Cardiovasc Res, May 1, 2009; 82(2): 324 - 332. [Abstract] [Full Text] [PDF]

				J. Igarashi and T. Michel Sphingosine-1-phosphate and modulation of vascular tone Cardiovasc Res, May 1, 2009; 82(2): 212 - 220. [Abstract] [Full Text] [PDF]

				A. Skoura and T. Hla Regulation of vascular physiology and pathology by the S1P2 receptor subtype Cardiovasc Res, May 1, 2009; 82(2): 221 - 228. [Abstract] [Full Text] [PDF]

				B. Levkau Sphingosine-1-Phosphate in the Regulation of Vascular Tone: A Finely Tuned Integration System of S1P Sources, Receptors, and Vascular Responsiveness Circ. Res., August 1, 2008; 103(3): 231 - 233. [Full Text] [PDF]

				K. M. Argraves and W. S. Argraves HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects J. Lipid Res., November 1, 2007; 48(11): 2325 - 2333. [Abstract] [Full Text] [PDF]

				K. R. Watterson, K. M. Berg, D. Kapitonov, S. G. Payne, A. S. Miner, R. Bittman, S. Milstien, P. H. Ratz, and S. Spiegel Sphingosine-1-phosphate and the immunosuppressant, FTY720-phosphate, regulate detrusor muscle tone FASEB J, September 1, 2007; 21(11): 2818 - 2828. [Abstract] [Full Text] [PDF]

				T. H. Westhoff, S. Schmidt, P. Glander, L. Liefeld, S. Martini, G. Offermann, H. H. Neumayer, W. Zidek, M. van der Giet, and K. Budde The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2354 - 2358. [Abstract] [Full Text] [PDF]

				N. K. Hudson, M. O'Hara, H. A. Lacey, J. Corcoran, D. G. Hemmings, M. Wareing, P. Baker, and M. J. Taggart Modulation of Human Arterial Tone During Pregnancy: The Effect of the Bioactive Metabolite Sphingosine-1-Phosphate Biol Reprod, July 1, 2007; 77(1): 45 - 52. [Abstract] [Full Text] [PDF]

				J. S. Isenberg, F. Hyodo, K.-I. Matsumoto, M. J. Romeo, M. Abu-Asab, M. Tsokos, P. Kuppusamy, D. A. Wink, M. C. Krishna, and D. D. Roberts Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation Blood, March 1, 2007; 109(5): 1945 - 1952. [Abstract] [Full Text] [PDF]

				H. Kume, N. Takeda, T. Oguma, S. Ito, M. Kondo, Y. Ito, and K. Shimokata Sphingosine 1-Phosphate Causes Airway Hyper-Reactivity by Rho-Mediated Myosin Phosphatase Inactivation J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 766 - 773. [Abstract] [Full Text] [PDF]

				J. N. Lorenz, L. J. Arend, R. Robitz, R. J. Paul, and A. J. MacLennan Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R440 - R446. [Abstract] [Full Text] [PDF]

				A. C.M. Mulders, M. C. Hendriks-Balk, M.-J. Mathy, M. C. Michel, A. E. Alewijnse, and S. L.M. Peters Sphingosine Kinase-Dependent Activation of Endothelial Nitric Oxide Synthase by Angiotensin II Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2043 - 2048. [Abstract] [Full Text] [PDF]

				S.-Z. Xu, K. Muraki, F. Zeng, J. Li, P. Sukumar, S. Shah, A. M. Dedman, P. K. Flemming, D. McHugh, J. Naylor, et al. A Sphingosine-1-Phosphate-Activated Calcium Channel Controlling Vascular Smooth Muscle Cell Motility Circ. Res., June 9, 2006; 98(11): 1381 - 1389. [Abstract] [Full Text] [PDF]

				E. Q. Scherer, D. Lidington, E. Oestreicher, W. Arnold, U. Pohl, and S.-S. Bolz Sphingosine-1-phosphate modulates spiral modiolar artery tone: A potential role in vascular-based inner ear pathologies? Cardiovasc Res, April 1, 2006; 70(1): 79 - 87. [Abstract] [Full Text] [PDF]

				D. G. Hemmings, N. K. Hudson, D. Halliday, M. O'Hara, P. N. Baker, S. T. Davidge, and M. J. Taggart Sphingosine-1-Phosphate Acts via Rho-Associated Kinase and Nitric Oxide to Regulate Human Placental Vascular Tone Biol Reprod, January 1, 2006; 74(1): 88 - 94. [Abstract] [Full Text] [PDF]

				C. G. Egan, C. L. Wainwright, R. M. Wadsworth, and G. F. Nixon PDGF-induced signaling in proliferating and differentiated vascular smooth muscle: Effects of altered intracellular Ca2+ regulation Cardiovasc Res, August 1, 2005; 67(2): 308 - 316. [Abstract] [Full Text] [PDF]

				S.-H. Hsiao, P. D. Constable, G. W. Smith, and W. M. Haschek Effects of Exogenous Sphinganine, Sphingosine, and Sphingosine-1-Phosphate on Relaxation and Contraction of Porcine Thoracic Aortic and Pulmonary Arterial Rings Toxicol. Sci., July 1, 2005; 86(1): 194 - 199. [Abstract] [Full Text] [PDF]

				M. Tolle, B. Levkau, P. Keul, V. Brinkmann, G. Giebing, G. Schonfelder, M. Schafers, K. v. W. Lipinski, J. Jankowski, V. Jankowski, et al. Immunomodulator FTY720 Induces eNOS-Dependent Arterial Vasodilatation via the Lysophospholipid Receptor S1P3 Circ. Res., April 29, 2005; 96(8): 913 - 920. [Abstract] [Full Text] [PDF]

				K. Lockman, J. S. Hinson, M. D. Medlin, D. Morris, J. M. Taylor, and C. P. Mack Sphingosine 1-Phosphate Stimulates Smooth Muscle Cell Differentiation and Proliferation by Activating Separate Serum Response Factor Co-factors J. Biol. Chem., October 8, 2004; 279(41): 42422 - 42430. [Abstract] [Full Text] [PDF]

				T. Tanimoto, A. O. Lungu, and B. C. Berk Sphingosine 1-Phosphate Transactivates the Platelet-Derived Growth Factor {beta} Receptor and Epidermal Growth Factor Receptor in Vascular Smooth Muscle Cells Circ. Res., April 30, 2004; 94(8): 1050 - 1058. [Abstract] [Full Text] [PDF]

				H. M. ROSENFELDT, Y. AMRANI, K. R. WATTERSON, K. S. MURTHY, R. A. PANETTIERI JR, and S. SPIEGEL Sphingosine-1-phosphate stimulates contraction of human airway smooth muscle cells FASEB J, October 1, 2003; 17(13): 1789 - 1799. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 91/2/151    most recent 01.RES.0000028150.51130.36v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coussin, F. Articles by Nixon, G. F. Search for Related Content PubMed PubMed Citation Articles by Coussin, F. Articles by Nixon, G. F. Related Collections Calcium cycling/excitation-contraction coupling Cell signalling/signal transduction